Actively Recruiting
Comparing Intravenous Racemic Ketamine and Nasal Esketamine for Treatment-Resistant Depression
Led by Yale University · Updated on 2026-09-08
400
Participants Needed
8
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating and comparing two treatments for patients with treatment-resistant depression TRD intravenous racemic ketamine and intranasal Esketamine Spravato4. This study aims to assess how effective each treatment is at reducing depression symptoms, how acceptable they are to patients, and how well patients tolerate any side effects. The study also explores factors that might predict which treatment works better for certain individuals. It is a randomized, multi-site, phase 3 comparative effectiveness trial enrolling about 400 adult participants. Participants will be randomly assigned to receive either racemic ketamine or Esketamine Spravato. Racemic ketamine will be administered intravenously over 40 minutes with a maximum dose of 60 mg per day and a lifetime limit of 8 doses. Esketamine will be given as a nasal spray with doses ranging from 56 to 84 mg, with allowances to reduce to 28 mg if needed for tolerance. The treatment period spans 4 weeks with dosing sessions following FDA guidelines. Throughout the study, participants will be monitored regularly for changes in their depression symptoms using self-reported and clinician assessments. Researchers will evaluate response, remission, suicidal ideation, disability level, quality of life, healthcare use, acceptability, global severity, improvement, tolerability, and safety over the treatment period. The primary outcome is self-reported effectiveness at 30 days. Participants will be followed for the duration of the trial, which lasts up to 5 years in total.
CONDITIONS
Brief Title
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
Research Team
C
Cindy Voghell
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here